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Formation of disulphide bonds within the mammalian
endoplasmic reticulum (ER) requires the combined activ-
ities of Ero1a and protein disulphide isomerase (PDI). As
Ero1a produces hydrogen peroxide during oxidation, reg-
ulation of its activity is critical in preventing ER-generated
oxidative stress. Here, we have expressed and puriﬁed
recombinant human Ero1a and shown that it has activity
towards thioredoxin and PDI. The activity towards PDI
required the inclusion of glutathione to ensure sustained
oxidation. By carrying out site-directed mutagenesis of
cysteine residues, we show that Ero1a is regulated by
non-catalytic disulphides. The midpoint reduction poten-
tial (E10) of the regulatory disulphides was calculated to be
approximately  275mV making them stable in the redox
conditions prevalent in the ER. The stable regulatory
disulphides were only partially reduced by PDI
(E10B 180mV), suggesting either that this is a mechan-
ism for preventing excessive Ero1a activity and oxidation
of PDI or that additional factors are required for Ero1a
activation within the mammalian ER.
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Introduction
The endoplasmic reticulum (ER) of mammalian cells contains
a number of enzymes, the role of which is to ensure efﬁcient
formation of native disulphide bonds in proteins entering the
secretory pathway. Central to the formation of disulphides is
the initial oxidation of cysteine residues catalysed by protein
disulphide isomerase (PDI) (Freedman, 1995). PDI is one of a
large family of homologous oxidoreductases present within
the ER (Ellgaard and Ruddock, 2005). Oxidation by PDI
results in the introduction of a disulphide into the substrate
protein with the concomitant reduction of a disulphide within
one of the active sites in PDI (Kulp et al, 2006). A second
enzyme, Ero1a or Ero1b in mammalian cells (Cabibbo et al,
2000; Pagani et al, 2000), is thought to catalyse the reoxida-
tion of the PDI active site (Sevier and Kaiser, 2002). The Ero1
enzymes are ﬂavoproteins that can couple the introduction of
a disulphide into PDI with the reduction of oxygen to liberate
hydrogen peroxide (Gross et al, 2006). Hence, for every
disulphide introduced into a substrate protein one molecule
of hydrogen peroxide theoretically can be produced by Ero1,
providing a potential source of reactive oxygen species (ROS)
and ER-generated oxidative stress (Chakravarthi et al, 2006).
To prevent the deleterious accumulation of ROS in the ER
lumen, the enzymatic activity of Ero1 needs to be tightly
regulated. Ero1a and Ero1b levels are regulated by hypoxia
(Gess et al, 2003) and the unfolded protein response (UPR)
(Pagani et al, 2000), respectively, providing a mechanism for
responding to changing conditions within the ER. Yeast Ero1
(Ero1p) is also regulated by the UPR (Frand and Kaiser, 1998;
Pollard et al, 1998) but, in addition, is regulated post-transla-
tionally by the formation of non-catalytic disulphides that
need to be reduced to activate the enzyme (Sevier et al,
2007). Such a mechanism allows the enzyme to be activated
during conditions when the ER is more reducing but inacti-
vated when oxidising conditions prevail. It is highly likely
that a similar system of regulation exists with the mammalian
Ero1 proteins; however, the cysteine residues outside the
active site are not conserved between the yeast and human
Ero1s (Sevier and Kaiser, 2008) making it difﬁcult to predict
which cysteines form the regulatory disulphides.
In addition to enzymes catalysing the oxidation of disul-
phide bonds, the ER lumen also contains enzymes that
catalyse the reduction or isomerisation of non-native disul-
phides (Jansens et al, 2002). PDI is able to catalyse both the
formation and reduction of disulphides (Freedman, 1995),
whereas other members of the PDI family of oxidoreductases
such as ERp57 may exert an effect primarily to resolve non-
native disulphides (Jessop et al, 2007). To catalyse these
reactions, the active site disulphides within these enzymes
need to be reduced. Indeed, most of the PDI family members,
apart from PDI, which is partially oxidised, are reduced at
steady state (Jessop and Bulleid, 2004). Glutathione (GSH) is
required to maintain such a reduced state, depletion of GSH
does not prevent disulphide formation but can lead to a
defect in folding due to a lack of resolution of non-native
disulphides (Chakravarthi et al, 2006). Hence, the ratio of
reduced to oxidised GSH (GSH/GSSG) must be sufﬁciently
reducing to maintain the ER oxidoreductases in a reduced
state, while allowing correct disulphide formation in
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2988substrate proteins. Ero1p can oxidise PDI even at quite high
GSH/GSSG ratios (Tu et al, 2000) potentially explaining how
both oxidation and reduction reactions can occur within the
same intracellular organelle. Interestingly, the phenotype of
the temperature-sensitive ero1-1 mutant can be suppressed by
perturbing the biosynthesis of GSH, suggesting that the
presence of this low molecular weight thiol increases the
load on Ero1p (Cuozzo and Kaiser, 1999). Although GSH is a
poor substrate for Ero1p, it can reduce oxidised PDI (Gilbert,
1989; Darby and Creighton, 1995), hence Ero1 could oxidise
GSH indirectly through the oxidation of PDI or other PDI
family members.
In this study, we set out to identify the regulatory disul-
phides within human Ero1a and to evaluate the ability of
GSH and PDI to activate the enzyme. To be able to character-
ise Ero1a, we puriﬁed full-length recombinant protein
expressed in Escherichia coli and characterised its activity
towards thioredoxin and PDI. We found that although thior-
edoxin was an excellent substrate for the enzyme, PDI
required the presence of GSH for sustained activity. In addi-
tion, the regulatory disulphides were shown to have a mid-
point reduction potential of approximately  275mV, making
these disulphides relatively stable within the ER lumen. Such
a low reduction potential explains why PDI partially reduces
this disulphide and raises the possibility of an additional
regulatory mechanism for Ero1a.
Results
Characterisation of recombinant Ero1a
To be able to characterise the enzymatic activity, regulatory
disulphides and biophysical properties of Ero1a, we ﬁrst
needed to produce sufﬁcient puriﬁed protein. To this end,
we expressed and puriﬁed the full-length protein in the
Origami B(DE3)pLysS strain of E. coli. Both the wild-type
and several mutant proteins containing single- or double-
point mutations changing individual cysteine residues to
alanine were soluble and expressed efﬁciently, unless stated
otherwise. All proteins contained similar amounts of bound
FAD with a protein/FAD ratio of approximately 1:0.85. An
absorbance scan of the puriﬁed wild-type protein revealed a
peak at 454nm characteristic of a bound FAD moiety
(Supplementary Figure S1A). The puriﬁed protein was ana-
lysed by multi-angle light scattering coupled to gel ﬁltration.
A single major peak of 57kDa was observed along with a
minor peak of 99kDa, consistent with the majority of the
protein being monomeric with some dimerisation
(Supplementary Figure S1B). These results are consistent
with previous data, which suggest that the Ero1 family
member, Ero1b, can form a dimer (Dias-Gunasekara et al,
2005). The folding characteristics of the protein was analysed
by CD (Supplementary Figure S2A), conﬁrming that the
secondary structure was dominated by a-helices (minima at
208 and 222nm), as expected from the known structure of
the Ero1p (Gross et al, 2004). In addition, we determined the
intact mass of the recombinant wild-type protein by ESI-TOF
mass spectrometry giving a value of 52945Da (mass accu-
racy ±2Da). This compares with a predicted mass of
52960Da, indicating that up to seven disulphides had formed
(the wild-type protein has 15 cysteine residues). We also
carried out an Ellman’s assay on the denatured wild-type
protein to determine the number of free thiol groups (Ellman,
1959). The result indicated that there were approximately
three free thiols per molecule, indicating that six disulphides
had formed. In addition, recombinant Ero1a migrated as a
single species by rpHPLC (Supplementary Figure S2B) with a
retention time distinct from the reduced protein, indicating
that a single disulphide-bonded species was present.
Previous work with yeast recombinant Ero1p (Sevier et al,
2007) and with mammalian Ero1s (Benham et al, 2000) has
demonstrated that the hydrodynamic volume of the dena-
tured protein changes signiﬁcantly on reduction of long-range
disulphide bonds. These disulphides have been shown to be
regulatory within Ero1p with their reduction causing an
activation of enzymatic activity (Sevier et al, 2007). A large
shift in mobility was seen when recombinant Ero1a was
separated on non-reducing gels either before or after reduc-
tion with 12.5mM dithiothreitol (DTT) for 5min (see gel inset
Supplementary Figure S2A). This result strongly suggests that
the recombinant protein contains long-range disulphides. An
obvious change in overall secondary structure of the native
protein did not occur on reduction as judged by CD as both
the untreated and protein treated with 12.5mM DTT gave
identical spectra (Supplementary Figure S2A). However, an
increase in the intrinsic tryptophan/tyrosine ﬂuorescence
was observed for the wild-type protein on reduction of the
long-range disulphides (Supplementary Figure S2C), demon-
strating that a change does occur in the microenvironment
around aromatic residues. These results suggest that the
breaking of long-range disulphides within Ero1a does not
cause gross changes to secondary structure in the native
protein but are consistent with a conformational change
giving rise to enzyme activation.
Recombinant Ero1a activity assays
To characterise the enzymatic properties of recombinant
Ero1a, we assayed the ability of the enzyme to oxidise
thioredoxin or PDI. The thioredoxin assay directly measures
the redox state of the substrate by using a gel-based assay
(Sevier et al, 2007). Thioredoxin is modiﬁed with the thiol-
alkylating agent 4-acetamido-40-maleimidylstilbene-2,20-di-
sulphonic acid (AMS), which increases the mass so that the
modiﬁed, reduced protein migrates slower through the gel
than oxidised protein. Complete oxidation of thioredoxin
occurred after 10min in the presence of Ero1a (Figure 1A,
lane 7); however, no thioredoxin was oxidised in the absence
of Ero1a (Figure 1A, lanes 2–8). To determine the redox state
of Ero1a during the reaction with thioredoxin, we assayed
changes in its electrophoretic mobility under non-reducing
conditions (Figure 1B). At the beginning of the reaction,
Ero1a is fully oxidised (Figure 1B, lane 1); however, after
20s most of the Ero1a migrates slower through the gel,
indicating reduction of long-range disulphides (Figure 1B,
lane 2). As the thioredoxin substrate becomes fully oxidised,
the long-range disulphides in Ero1a reform so that after
1200s most of the Ero1a are oxidised (Figure 1B, lane 7).
There was a distinct lag between the oxidation of thioredoxin
and the change in redox status of Ero1a; at 400s most of the
thioredoxin is oxidized, yet the Ero1a regulatory disulphides
are still partially reduced (Figure 1A and B). Hence, the rate
of reformation of the Ero1a regulatory disulphide is slower
than the oxidation of thioredoxin by Ero1a. These results
mirror what happens with Ero1p (Sevier et al, 2007), strongly
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way to the yeast protein.
Having shown that recombinant Ero1a is active towards
thioredoxin, we then wanted to see whether it had activity
towards its physiological substrate, PDI. To assay activity, we
ﬁrst monitored the consumption of oxygen when PDI was
incubated in the presence of Ero1a, either in the presence or
absence of GSH (Figure 2A and B). We found that in the
absence of GSH the rate of oxygen consumption was initially
faster than the rate in the absence of Ero1 but quickly ceased
(Figure 2A) after consumption of approximately 40mM oxy-
gen. Given the fact that the assay contains 100mM PDI with
two active sites, this consumption of oxygen indicates that
only 20% of the active sites were oxidised. However, in the
presence of GSH, oxygen was consumed for a much more
prolonged period of time, so even in the presence of 10mM
GSH, Ero1a was active towards PDI. The maximal turnover
number was found to be approximately three disulphides per
molecule of Ero1a per minute, which although low, compares
well with the turnover rate for Ero1p assayed under identical
conditions (Sevier et al, 2007). It should be noted that not all
the oxygen is consumed during the reaction with PDI even in
the presence of GSH (Figure 2B). Here, approximately 160mM
oxygen was consumed, which equates to 80% of the PDI
active sites oxidised.
It has been shown earlier that Ero1p displays distinct
reactivity towards the two active sites of yeast PDI (Kulp
et al, 2006). We also found that the mammalian enzyme
differentially oxidised the two active sites in PDI (Figure 2C).
When mutant PDI containing a CGHC to SGHA mutation in
the ‘a’ domain active site (DS1) was incubated with Ero1a
and GSH, wild-type rates of oxygen consumption were ob-
served. However, a similar mutation of the a0 domain (DS2)
greatly diminished the rate of oxygen consumption. It would
appear from these results that Ero1a preferentially oxidises
the a0 domain of PDI.
To explain these results further, we determined whether
PDI was being oxidised by Ero1a using a similar gel-based
assay as used with thioredoxin. Unfortunately, the redox state
of human PDI cannot be assayed using AMS as the difference
in mobility of the reduced and oxidised forms is minimal
(Mezghrani et al, 2001; Chakravarthi and Bulleid, 2004).
However, the redox state can be determined using an assay
based on the modiﬁcation of cysteine residues using methoxy
polyethyleneglycol 5000 maleimide (mPEG-mal) (Xiao et al,
2004; Appenzeller-Herzog and Ellgaard, 2008). In this assay,
the two non-active site thiols and four active site thiols are
modiﬁed if PDI is fully reduced resulting in a dramatic
increase in mass and an increase in Coomassie blue staining
(Figure 3A, lanes 1 and 2). If PDI is oxidised, then additional
Figure 2 Ero1a oxidises PDI and shows selectivity towards the a0
active site. (A) Kinetics of oxygen consumption by Ero1a (2mM)
during reaction with reduced PDI (100mM) was assayed either in the
absence (A) or presence (B) of GSH (10mM). Control reactions
following oxygen consumption in the absence of Ero1a are as
indicated. (C) The oxygen consumption by Ero1a (2mM) during
reaction with either a DS1 or DS2 mutant of PDI in the presence of
10mM GSH. The experiments were carried out three times with
similar activity proﬁles.
Figure 1 The redox state of Ero1a changes transiently during the
efﬁcient oxidation of thioredoxin. (A) Ero1a oxidises Trx1 (100mM)
as conﬁrmed by the change of redox status judged by alkylation
with AMS when incubated in the presence of Ero1a (0.5mM) but not
in its absence. Proteins were visualised by reducing SDS–PAGE and
Coomassie blue staining. (B) Ero1a is transiently reduced following
incubation with Trx1. Reactions were quenched with NEM, the
redox state of Ero1a was visualised by non-reducing SDS–PAGE and
silver staining. The reduced and oxidised forms of thioredoxin and
Ero1a are indicated as r and ox, respectively. (A, B) Representative
gels; the experiment was repeated at least three times with similar
results.
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incubated alone, no additional faster migrating species were
seen after 60min (Figure 3A, lanes 2 and 3). However, on
addition of Ero1a, faster migrating, oxidised forms of PDI
were apparent both in the absence and presence of GSH
(Figure 3A, lanes 4–7). Several different mPEG-modiﬁed
forms were apparent, suggesting that intermediate oxidation
states of PDI were present even after 60min of incubation
with Ero1a. The most prominent oxidised species co-mi-
grated with fully reduced and mPEG-modiﬁed DS2 mutant
PDI (Figure 3A, lane 9), which migrates with a distinct
mobility to the reduced DS1 mutant (lane 8) as described
earlier (Appenzeller-Herzog and Ellgaard, 2008). Oxidation of
the a0 domain would prevent mPEG modiﬁcation of this
active site, so the mobility of the protein would be identical
to the reduced DS2 mutant. This result further supports the
idea that the a0 domain is preferentially oxidised by Ero1a.
Unlike the situation with thioredoxin, PDI was not quantita-
tively oxidised by Ero1a with the fully reduced form present
even after 60min.
To determine whether PDI can reduce the regulatory dis-
ulphide within Ero1a, we determined the redox state of Ero1a
during its reaction with PDI both in the presence and absence
of GSH (Figure 3B). In the absence of GSH, PDI reduces only
a fraction of the available Ero1a in the ﬁrst 10min, which can
then become reoxidised (Figure 3B, lanes 1–4). This result is
consistent with the oxygen consumption assay and supports
the idea that PDI can partially reduce the long-range disul-
phides in Ero1a. In the presence of GSH, PDI again reduces
only a fraction of Ero1a and this fraction remains reduced
over the 60min (Figure 3B, lanes 5–7). If we assume that the
long-range disulphides are regulating Ero1a activity (see
later), then PDI is no more able to activate Ero1a in the
presence of GSH than in its absence. However, in the pre-
sence of GSH, PDI can activate sufﬁcient Ero1a to maintain
activity, presumably because GSH can continually reduce
PDI. We also determined whether GSH itself can reduce the
regulatory disulphide in Ero1a. At concentrations of GSH up
to 10mM, there was minimal reduction of Ero1a (Figure 3C)
and the regulatory disulphides were only fully reduced at
concentrations above 100mM. Hence, GSH itself cannot
activate Ero1a at physiological concentration possibly ex-
plaining why this low molecular weight thiol is a poor
substrate for Ero1a.
Identiﬁcation of regulatory disulphides within Ero1a
Human Ero1a contains 15 cysteine residues, of which four
are within two active sites (Bertoli et al, 2004). Previous
mutagenesis studies have identiﬁed the active site disul-
phides to be between cys394–397 and cys94–99 with cys85,
cys391 and cys131 affecting the redox state of Ero1a at steady
state when transiently expressed in mammalian cells (Bertoli
et al, 2004). The regulatory disulphides within Ero1p form
between cys90–349 and cys150–295 (Sevier et al, 2007). In
human Ero1a, the ﬁrst of these disulphides is conserved in
the primary amino-acid sequence so it was assumed that
cys85–391 will form one regulatory disulphide. However,
additional regulatory disulphide(s) cannot be predicted
from comparison of the yeast and human sequences.
Hence, to identify the cysteine residues involved, we con-
verted individual cysteines to alanine and determined
whether these mutations result in a change in the long-
range disulphides formed in recombinant Ero1a. The ﬁrst
cluster of cysteine residues (cys35, 37, 46 and 48) were not
analysed as the corresponding region of the protein in Ero1p
can be deleted without any effect on regulation (Sevier et al,
2007). Of all the remaining non-active site cysteine mutants,
only C391A and C85/391A did not form soluble protein when
expressed in E. coli. In addition, the C85A mutant gave a poor
yield and was intrinsically unstable on storage, restricting the
analysis to its redox status on non-reducing gels. When the
cysteine mutant proteins were analysed on non-reducing gels
and their mobility was compared with that of oxidised and
reduced wild-type proteins, C85A, C94A, C131A and to a
Figure 3 Ero1a oxidises PDI but the long-range disulphides in
Ero1a are only partially reduced. (A) The oxidation of PDI by
Ero1a was followed by the change in redox state of reduced PDI
as judged by the access of free thiols to alkylation by mPEG-mal.
Reduced PDI (100mM) was incubated in the absence (lanes 2 and 3)
or presence (lanes 4–7) of Ero1a and in the absence (lanes 2–5) or
presence (lanes 6 and 7) of GSH (10mM). Reactions proceeded for 5
or 60min as indicated before being terminated by the addition of
TCA followed by alkylation with mPEG-mal. Protein was separated
by reducing SDS–PAGE and visualised by Coomassie staining. An
untreated and mPEG-mal-treated reduced PDI sample (lanes 1 and
2) and an mPEG-mal-treated sample of reduced DS1 and DS2
mutants of PDI (lanes 8 and 9) are shown to indicate the mobility
shift on mPEG-mal modiﬁcation of reduced PDI. (B) The redox state
of Ero1a was assayed during the reaction with PDI either in the
absence (lanes 1–4) or presence (lanes 5–7) of GSH (10mM).
Reactions were quenched with NEM and the redox state of Ero1a
was visualised by non-reducing SDS–PAGE followed by western
blotting with an anti-Ero1a antibody. Thioredoxin-reduced Ero1a
was loaded in lane 8 for comparison. (C) The redox state of Ero1a
was determined after incubation (15min) with increasing concen-
trations of GSH (titrated to pH 7.5) as indicated. Reactions were
quenched with NEM and the redox state of Ero1a was visualised by
non-reducing SDS–PAGE and silver staining. The experiments in
(A–C) were repeated three times with similar results obtained.
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an intermediate mobility between the reduced and oxidised
wild-type proteins (Figure 4A). The fact that the single
cysteine mutants gave rise to two bands indicates that alter-
nate cysteines may be able to form disulphides to generate
new long-range disulphides. The shift in mobility with C85A
was expected as cys85 was predicted to form a long-range
disulphide with cys391, so the second regulatory disulphide
was hypothesised to be between cys131, 94 or possibly 104.
A double mutation C94/99A ran as a single band with a
mobility corresponding to the slowest band in the single
mutants C94A and C131A (Figure 4A, lane 12). These results
suggest that cys94 is the partner for cys131 and that the
presence of two bands with the C94A mutant could be due to
cys99 behaving as an alternate partner for cys131. In addi-
tion, a double mutation C85/131A ran even slower through
the gel (Figure 4A, lane 11), indicating that this mutant was
now unable to form two long-range disulphides. The slight
difference in mobility between C85/131A and the fully re-
duced wild-type protein is likely to be due to other disul-
phides still present in the double mutant. The results
obtained from the gel shift assay have recently been con-
ﬁrmed independently (Appenzeller-Herzog et al, 2008). They
identiﬁed disulphide bonds between cys85–391 and cys94–
131 by mass spectrometry analysis of Ero1a puriﬁed from
human cells. The data, however, do not rule out the possibi-
lity of further disulphides involved in the modulation of
Ero1a activity.
We also assessed whether the cysteine mutants gave the
same changes in tryptophan/tyrosine ﬂuorescence when
reduced, as the wild-type protein. Both the C131A and the
C85/131A showed no increase in ﬂuorescence at 345nm
(Figure 5A, panels 2 and 3) on reduction with 12.5mM
DTT, indicating that there were no major conformational
changes to the micromolecular environment of the trypto-
phan/tyrosine residues on DTT treatment. However, the
C104A mutant did show a change in ﬂuorescence on reduc-
tion, very similar to the wild-type protein (Figure 5A, panel
1), indicating that cys104 does not form a disulphide bond
that affects tryptophan/tyrosine ﬂuorescence. Taken together,
these results support the idea that cys94 and cys131 form a
disulphide bond that when broken is sufﬁcient to cause the
change in conformation giving rise to an increase in trypto-
phan/tyrosine ﬂuorescence.
To determine whether the long-range disulphides regulated
enzymatic activity, we carried out enzyme assays using
thioredoxin and PDI as substrates. Only the C94/99A double
mutant and the C99A mutant showed a total lack of activity
towards thioredoxin (Supplementary Figure S3).
Interestingly, C94A did have some weak activity towards
thioredoxin consistent with previous data, which suggest
that this mutant is weakly active in an in vivo folding assay
and can complement the yeast ero1-1 mutant (Bertoli et al,
2004). All the cysteine mutants outside the active site were
enzymatically active, indicating that they had folded cor-
rectly. However, the thioredoxin assay could not distinguish
whether the mutants had an enhanced activity. To further
evaluate the potential regulatory disulphides, we determined
the activity of C131A and C85/131A towards PDI in the
presence of GSH using the oxygen consumption assay
(Figure 5B). C131A showed a clear difference in kinetics
when compared with wild type (Figure 5B, panel 1) lacking
both a lag phase and having a greater rate of oxygen turnover
(about twice that of wild type). In addition, the activity of the
C85/131A towards PDI was signiﬁcantly quicker than wild-
type Ero1a (Figure 5B, panel 2). Our conclusion from these
Figure 4 Identiﬁcation of the cysteine residues involved in the formation of long-range disulphides in Ero1a.( A) Reduced (lanes 10 and 14)
and non-reduced (lanes 1 and 13) wild-type Ero1a were separated by SDS–PAGE along with non-reduced cysteine mutants of Ero1a as
indicated. Protein was visualised following SDS–PAGE and Coomassie staining. (B) Schematic illustration comparing the disulphide bonds
within human Ero1a and yeast Ero1p that are either active site disulphides ( ) or regulatory disulphides ( ). Known disulphide pairings are as
indicated as they exist in the inactive state of the protein. Note that in the human protein cys94 and cys99 are engaged in disulphide pairings
with cys131 and cys104, respectively, whereas in the active state these would form a disulphide with each other.
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disulphides cys85–391 and cys94–131 are regulatory as their
reduction results in a cumulative increase in the activity of
Ero1a towards PDI.
The fact that cys94 forms a regulatory disulphide with
cys131 means that in its inactive state Ero1a, cys99 and
cys104 could potentially form a disulphide. Our gel shift
data with the C104A mutant suggest that breaking this
potential disulphide could destabilise the cys94–cys131 dis-
ulphide. In addition, the activity of the C131A mutant protein
could also be modulated by the formation of a cys99–cys104
disulphide. To test this possibility, we made a further Ero1a
mutation, C104/131A. When the activity of this mutant was
tested in the oxygen electrode assay, we now obtained even
faster kinetics than the C85/131A mutant (Figure 5B, panel
3), suggesting that a disulphide does indeed exist between
cys99 and cys104, which can also modulate Ero1a activity. In
addition, we now saw almost complete consumption of
oxygen during the assay, which contrasts with the wild-type
protein and the C85/131A mutant (Figure 5B). These results
would suggest that the lack of complete consumption of
oxygen with the wild-type protein and C85/131A mutant is
due to the formation of a disulphide between cys104 and
cys99, which is not efﬁciently reduced even in the presence of
GSH. A schematic diagram illustrating the positions of the
active site and regulatory disulphides in Ero1a and Ero1p is
shown in Figure 4B.
Determining the reduction potential of the regulatory
disulphide bonds
To ascertain whether the lack of efﬁcient reduction of the
regulatory disulphides in Ero1a by PDI could be attributed to
their relative stability, we set out to determine their reduction
potential. We used thioredoxin as a redox couple as it
efﬁciently reduces Ero1a. In addition, we used the C99A
mutant of Ero1a as it is inactive towards thioredoxin
(Supplementary Figure S3) ensuring no changes to thioredox-
in redox state due to enzymatic activity. In addition, this
mutant will not contain the potential cys99–104 disulphide.
Ero1a was incubated with various ratios of reduced/oxidised
thioredoxin and the redox state was evaluated by non-redu-
cing gel analysis. A clear transition from reduced to
oxidised Ero1a was seen as the ratio of reduced/oxidised
thioredoxin decreased (Figure 6A). The equilibrium constant
(Keq) was calculated to be 2.10±0.64 (average and standard
deviation from three separate measurements) (Figure 6B).
Only a single transition in the redox state of Ero1a
was observed, indicating that the breaking of the regulatory
disulphides occurs at a similar reduction potential.
Assuming that two molecules of thioredoxin are required to
reduce the cys85–391 and cys94–131 disulphides, the calcu-
lated midpoint reduction potential would be  275mV.
The stability of the disulphide suggests it would be oxidised
within the ER and in part explains its partial reduction
by PDI.
Figure 5 Ero1a long-range disulphides regulate conformation changes and enzymatic activity. (A) The ﬂuorescence emission spectra of
reduced (grey line) or non-reduced (black line) Ero1a mutants C104A (1), C131A (2) and C85/131A (3) were analysed following excitation at
280nm. (B) Oxygen consumption was assayed with PDI (100mM) in the presence of 10mM GSH and the Ero1a mutants (2mM) C131A (1), C85/
131A (2) or C104/131 (3). These are representative proﬁles from three separate experiments. The activity of wild-type Ero1a towards PDI is also
included in each graph as indicated.
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Previous work has demonstrated that the enzymatic activity
of Ero1p can be regulated by the breaking and reforming of
two disulphide bonds (Sevier et al, 2007). Here, we show that
the human enzyme, Ero1a, is regulated in a similar manner
but, unlike the yeast enzyme, forms regulatory disulphides
between non-catalytic cysteines and cysteines located within
the ﬁrst active site. The formation of such bonds would
inevitably inhibit enzyme activity as the ﬁrst active site is
required to accept electrons from the substrate protein (Sevier
and Kaiser, 2006). The enzyme could only become active on
reduction of these disulphides, either by the substrate or by
an additional regulatory protein.
The initial identiﬁcation of regulatory disulphides within
Ero1p demonstrated that they were the same disulphides that
dramatically alter the hydrodynamic volume of the denatured
protein (Sevier et al, 2007). We also show that the same is
true for Ero1a and additionally demonstrate that breaking
these disulphides also alters the conformation of the native
protein. The reduction of the disulphides does not grossly
change the secondary structure but does alter the environ-
ment around speciﬁc aromatic residues thereby altering their
ﬂuorescence. The yeast structure has been solved (Gross
et al, 2004) and revealed a 10 helix core that contains the
bound FAD and second active site disulphide. The ﬁrst active
site disulphide (or shuttle disulphide), which accepts elec-
trons from substrates, is located on a non-helical loop that
forms a ‘cap’ over the helical core. Sevier et al (2007)
speculate that ‘the regulatory disulphides may tether a non-
helical cap, with the helical core of Ero1p’. The identiﬁcation
of cys94–131 as a regulatory disulphide is, therefore, some-
what unexpected as both residues would be expected to be in
the non-helical cap as judged by homology modelling (data
not shown). However, it is difﬁcult to make direct compar-
isons between the yeast and human enzyme in the absence of
structural data for the latter, as homology modelling between
the human and yeast proteins also predicts that cys94 and
cys131 are not close enough to form a disulphide.
The presence of an additional cysteine residue (cys104)
around the ﬁrst active site in Ero1a that is not present in the
yeast enzyme suggested an additional mechanism both for
Ero1a activity and for its regulation. The C94A mutant would
be predicted to be inactive if the cys94–99 disulphide is the
ﬁrst active site. However, we and others (Bertoli et al, 2004)
have shown that this mutant still has some weak activity,
suggesting that, in the absence of cys94, cys99 might form an
alternative disulphide with cys104, which is itself able to
accept electrons, albeit at a much reduced rate, from sub-
strate proteins. In addition, we noticed a partial reduction of
one of the long-range disulphides in the C104A mutant,
which could be due to cys99 being able to resolve the
cys94–131 disulphide if it is not paired with cys104. In
addition, when recombinant Ero1a was treated with N-ethyl-
maleimide (NEM), digested with trypsin and the peptides
were analysed by MALDI mass spectrometry, we consistently
observed a peptide with an internal disulphide between cys99
and cys104 (results not shown). The near complete oxygen
consumption seen with this mutant contrasts with a lack of
complete oxygen consumption by the wild-type protein or the
C85/131A mutant. This result suggests that the formation of a
cys99–104 disulphide may lead to the inhibition of Ero1a in
the in vitro assay. The ability of Ero1a to exchange internal
disulphide bonds may not be restricted to the two active sites,
indeed the ability to reform the regulatory disulphides in the
absence of substrate demonstrates that several disulphide
exchange reactions are not only possible but are also neces-
sary for the tight regulation of this enzyme.
We have extended the previous studies on Ero1p to de-
monstrate that the regulatory disulphides within Ero1a are
relatively stable, which means that only molecules capable of
forming an equally stable disulphide would be able to reduce
these bonds efﬁciently. Our activity data support this ﬁnding;
thioredoxin, which has a relatively stable active site disul-
phide, can readily reduce the regulatory disulphides in Ero1a,
whereas PDI with less stable active site disulphide can only
reduce a small fraction of Ero1a. The reduction potential of
PDI active sites has been calculated to be approximately
 180mV (Lundstrom and Holmgren, 1993), which means
that in the absence of additional factors PDI would need to be
over 99% reduced to be able to reduce the regulatory
disulphide in Ero1a. Once the regulatory disulphides are
broken, the enzyme is active until the regulatory disulphides
reform. The distinct lag between oxidation of thioredoxin and
the reformation of the regulatory disulphides in Ero1a sug-
gests that the rate of reformation of the inhibitory disulphide
is slower than the rate of oxidation of substrate. Hence, once
the enzyme is activated, it would be able to complete several
oxidation cycles prior to reformation of the regulatory dis-
ulphide. Although PDI may be able to activate Ero1a in our in
vitro assay due to the starting material being reduced, it is
unlikely to be true in vivo as PDI will be at least partially
oxidised. This argues for the presence of additional factors
regulating the activity of Ero1a in the ER lumen.
Alternatively, PDI binding to Ero1a may lead to conforma-
Figure 6 Measuring the midpoint reduction potential of the regu-
latory disulphides in Ero1a.( A) The enzymatically inactive C99A
mutant (1mM) was equilibrated with various ratios of reduced/
oxidised thioredoxin before alkylation with NEM and separation by
non-reducing SDS–PAGE. Protein was visualised by Coomassie
staining and the fraction of reduced Ero1a was quantiﬁed by
densitometry. (B) Values for the fraction of reduced Ero1a were
plotted against the ratio of reduced/oxidised thioredoxin. Plots were
interpreted by equation (1), and Keq values were determined as
described. The experiment was repeated three times and the
average Keq was used to calculate the reduction potential.
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potentials of the disulphides within Ero1a and PDI.
The ability of Ero1p to oxidise the individual active sites of
yeast PDI has been shown to be non-equivalent (Kulp et al,
2006). Ero1p preferentially oxidises the a0 domain of Pdi1p. We
also show that the a0 domain of human PDI is oxidised almost
exclusively by Ero1a, with little or no oxidation of the a domain.
Such a distinct speciﬁcity could result in distinct activities of the
active sites of PDI towards its substrates; the a domain acting as
an isomerase or reductase with the a0 domain acting as an
oxidase as suggested for Pdi1p (Kulp et al, 2006).
Our in vitro data demonstrate that although PDI is not fully
oxidised by Ero1a, the presence of GSH can prolong the
reaction. The mechanism underlying the ability of GSH to
facilitate the activity of Ero1a towards PDI is difﬁcult to
explain as GSH itself does not seem to be able to reduce the
regulatory disulphides and is a poor substrate for Ero1a even
though it has a lower reduction potential ( 240mV) than
PDI. It is likely that GSH will reduce the active site disul-
phides in PDI (Gilbert, 1989), so one possibility is that PDI is
reduced in the presence of GSH allowing further oxidation by
Ero1a, thereby prolonging oxygen consumption. Indeed, as
only one active site in PDI is efﬁciently oxidised by Ero1a and
there is 100mM PDI in the reaction, the fact that B160mM
oxygen is consumed would suggest that the PDI is being
reduced by GSH. Such a system may well operate in vivo with
the transfer of electrons between GSH and oxygen through
PDI and Ero1a ultimately leading to the formation of GSSG
and H2O2. In support of such a situation is the fact that the
depletion of GSH from yeast cells allows the temperature-
sensitive ero1-1 mutant to survive at the non-permissive
temperature and, in addition, the steady-state level of GSSG
is regenerated more quickly in cells that are overexpressing
Ero1p (Cuozzo and Kaiser, 1999). Given the differences in the
reduction potentials of the regulatory disulphide in Ero1a and
the active site disulphides in PDI, one would predict that,
similar to in vitro, only a small fraction of PDI would be fully
oxidised in vivo. Recent measurements of the redox state of
PDI estimate that only 16% of PDI present in mammalian
cells is fully oxidised at both active sites (Appenzeller-Herzog
and Ellgaard, 2008). It is interesting to note that yeast PDI is
predominantly oxidised in vivo (Xiao et al, 2004), suggesting
clear differences between the regulation of Ero1p and Ero1a
in terms of their ability to be activated and to oxidise PDI.
The concept that GSH is required to reduce PDI thereby
maintaining Ero1a activity does have problems when we
consider the situation within the lumen of the ER. If this
reaction were to go unchecked, one would establish a ‘futile
cycle’, which only requires GSH, PDI and Ero1a to continue
(Thorpe and Coppock, 2007). However, our in vitro data
show that Ero1a activity as measured by oxygen consump-
tion is inhibited at later time points even in the presence of
high concentrations of GSH. As mentioned above, this inhibi-
tion could be due to the formation of an additional disulphide
(cys99–104). Alternatively, an additional protein may be
required to reduce the regulatory disulphide in Ero1a; given
the low turnover rate of the enzyme in vitro, this may well be
the case. Clearly more work needs to be done to address these
issues, but the fact that the regulatory disulphide in Ero1a is
relatively stable suggests that this enzyme may have several
layers of regulation speciﬁcally to prevent ‘futile cycling’ with
GSH.
Materials and methods
Plasmid construction and mutagenesis of Ero1a
The Ero1a signal sequence was replaced with a hexahistidine tag
and the sequence coding for the full-length mature protein was
inserted into a pGEX-4T-3 vector (GE Healthcare) downstream from
the GST coding sequence to create a GST–His–Ero1a fusion.
Cysteine to alanine mutations for Ero1a were created using
Quickchange site-directed mutagenesis with Pfu DNA polymerase
(Stratagene). All constructs were veriﬁed by sequencing.
Expression and puriﬁcation of Ero1a
Ero1a was expressed in the Origami B (DE3)pLysS strain of E. coli.
Cells were grown in LB broth containing 100mg/ml ampicillin,
30mg/ml chloramphenicol, 10mg/ml tetracycline and 10mg/ml
kanamycin at 371C for 4–6h until an optical density of 1.0 was
reached. An additional 1/5 volume of LB and 20mg/ml ampicillin
was then added along with 10mM FAD and 0.5mM IPTG to induce
the expression of Ero1a and the culture was grown at 161C for 24h.
Pelleted cells were resuspended in 20ml ice-cold lysis buffer
(1mg/ml hen egg white lysozyme, 20mg/ml DNase I (Roche),
2.5mg/ml RNase A, two complete EDTA-free protease inhibitor
cocktail tablets (Roche), 1mM EDTA and 0.1% (v/v) Triton X-100 in
phosphate-buffered saline (PBS)) per 1l bacterial culture. The cells
were then lysed by freeze–thawing in liquid nitrogen and the lysates
were clariﬁed by centrifugation at 12760g for 15min. The soluble
fraction was incubated with 1ml of equilibrated glutathione
Sepharose beads (GE Healthcare) at 41C for 4h. The beads were
washed three times with 10 bed volumes of 1  PBS before being
mixed with 1ml of PBS containing 100U of thrombin (GE
Healthcare). Thrombin cleavage was left to proceed overnight at
41C with gentle agitation. The cleaved protein was buffer exchanged
using a PD10 column (GE Healthcare) into Ni-NTA-binding buffer
(50mm NaH2PO4 buffer, pH 8.0, 300mM NaCl and 2.5mM
imidazole).
Ni-NTA beads (0.5ml bed volume) (Qiagen) were added to
Ero1a in Ni-NTA-binding buffer and binding was carried out for
90min at 41C. The beads were washed twice with 10ml of Ni-NTA
wash buffer (50mM NaH2PO4 buffer, pH 8.0, 300mM NaCl and
20mM imidazole) before being eluted in the same buffer containing
250mM imidazole. The Ero1a was then buffer exchanged into
50mm Tris–HCl buffer, pH 7.5. Flavoprotein concentrations were
determined using the experimentally determined bound FAD
absorption coefﬁcient of 12.9mM
 1cm
 1 at 454nm (see Supple-
mentary data).
Expression and puriﬁcation of thioredoxin and PDI
A construct expressing His-tagged E. coli thioredoxin 1 (Trx1) in a
pET28 vector was obtained from Deborah Fass (Rehovot, Israel).
Trx1 was expressed, puriﬁed and reduced as described earlier
(Gross et al, 2006). The concentration of reduced Trx1 was
quantiﬁed using the Ellman’s assay (Ellman, 1959). Constructs
expressing His-tagged PDI and the DS1 and DS2 active site mutants
were obtained from Lloyd Ruddock (Oulu, Finland). PDI was
expressed and puriﬁed in the same manner as Trx1. PDI was
reduced for 1h with 10mm DTT and then buffer exchanged with a
PD10 column into 50mM Tris–HCl buffer, pH 7.5. PDI was
quantiﬁed using the 280nm PDI absorption extinction coefﬁcient
of 47.12mM
 1cm
 1 (Gill and von Hippel, 1989).
Electrophoresis and western blotting
Samples for SDS–PAGE were resuspended in SDS–PAGE sample
buffer (25mM Tris–HCl buffer, pH 6.8, 2% w/v SDS, 20% v/v
glycerol and 0.004% w/v bromophenol blue). Reduced samples
contained 50mM DTT. Gels were either transferred to a nitrocellu-
lose membrane for western blotting or stained with Coomassie blue
or silver stain. For western blotting, gels were transferred to
nitrocellulose and blocked using 3% milk in TBST (10mM Tris–HCl
buffer, 150mM NaCl, pH 7.5, 0.1% Tween-20). A rabbit polyclonal
antibody for Ero1a (from Adam Benham, Durham, UK) was used as
a primary antibody at a dilution of 1:500 in 1% milk. Products were
visualised using a chemiluminescent substrate (Perbio) and Fuji
Super RX ﬁlm (Fujiﬁlm).
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Oxygen consumption was measured using a Clark-type oxygen
electrode (Rank Brothers, Cambridge, UK). The chamber was
covered with foil to prevent photoreduction of ﬂavins. Assays with
PDI were carried out in 500ml using 100mM reduced PDI and 2mM
Ero1a in 50mM Tris–HCl buffer, pH 7.5 with or without 10mM
GSH.
Gel-based thioredoxin and PDI oxidation assays
Reactions with Trx1 were initiated by adding 0.5mM Ero1a to
100 mM reduced Trx1 in 50mM Tris–HCl, pH 7.5. At the indicated
times, reactions were quenched for 30min at room temperature
with an equal amount of SDS–PAGE sample buffer containing either
10mM AMS (Invitrogen) or 50mM NEM. Reactions quenched with
AMS were separated on 15% polyacrylamide gels and were stained
to visualise the redox state of Trx1. Samples quenched with NEM
were separated on 10% polyacrylamide gels and silver stained to
visualise the redox status of Ero1a. Reactions with PDI were carried
out using 100mM reduced PDI and 2mME r o 1 a in 50mM Tris–HCl
buffer, pH 7.5 with 10mM GSH where stated. Reactions were
terminated with 10% (v/v) trichloroacetic acid (TCA). Samples
were incubated on ice for 20min and then centrifuged at 12760g
for 10min. Supernatants were removed and protein pellets were
washed twice with ice-cold acetone before ﬁnally resuspending
the pellets in SDS–PAGE buffer containing mPEG for 30min (0.2M
Tris–HCl buffer, pH 6.8, 6% w/v SDS, 20% v/v glycerol, 0.004%
w/v bromophenol blue and 5mM mPEG-mal 5000 (Layson
Bio, US)). Reactions were visualised by SDS–PAGE and Coomassie
blue staining.
Redox state determination of Ero1a with PDI and GSH
Reactions with PDI were carried out in 50mM Tris–HCl buffer, pH
7.5 with 100mM reduced PDI and 2mME r o 1 a with or without
10mM GSH. At the indicated times, an equal amount of SDS–PAGE
sample buffer containing 50mM NEM was added to quench the
reactions. These reactions were diluted 1 in 40 into SDS–PAGE
sample buffer containing 10mM NEM to lower the amount of PDI
on the gel that otherwise distorts the running of the Ero1a. The
reactions were resolved through non-reducing SDS–PAGE followed
by western blotting with the anti-Ero1a antibody. For reactions of
Ero1a with GSH only, 2mME r o 1 a was incubated with varying
concentrations of GSH for 15min in a 50mM KPO4 buffer, pH 7.5.
Each GSH solution was neutralised to pH 7.5. Reactions were
quenched and precipitated with the addition of 10% v/v TCA before
ﬁnally resuspending the pellets in 20ml SDS–PAGE sample buffer
containing 25mM NEM.
Redox potential determination of Ero1a regulatory
disulphides
The C99A mutant was used to determine the redox potential of the
regulatory disulphides in Ero1-La.C 9 9 AE r o 1 a (1mM) was left to
equilibrate with 100mM Trx1 with varying ratios of reduced/oxidised
Trx1 for 1h 30min. As a control for air oxidation, we incubated
reduced thioredoxin in buffer for 1h 30min. No change in the
oxidation state of thioredoxin was found after this time as judged by
assay with Ellman’s reagent (Ellman, 1959) and less than 1%
change was seen as judged by rpHPLC (data not shown). Such a low
level of air oxidation does not affect the calculation of the
equilibrium constant. Oxidised Trx1 was prepared by incubating
Trx1 for 1h with 10mM GSSG and reduced Trx1 was prepared by
incubating with 10mM DTT before buffer exchange using Micron
centrifugal YM10 ﬁlters (500ml concentrated to 10ml three times to
give a ﬁnal concentration of o80nM DTT or GSSG). The
concentrations of reduced and oxidised Trx1 were determined using
the Bradford assay (Bradford, 1976). Reactions were quenched with
an equal amount of SDS–PAGE buffer containing 50mM NEM. The
redox state of Ero1a was determined by non-reducing SDS–PAGE.
The amount of reduced Ero1a in each reaction was determined by
densitometry and expressed as a fraction of total Ero1a. The
equilibrium constant Keq for the redox reaction was calculated
according to equation (1) assuming two molecules of thioredoxin
are required to reduce the two long-range disulphides in Ero1a.
R ¼ð ½ Trxred 2=½Trxox 2Þ=ðKeq þ½ Trxred 2=½Trxox 2Þð 1Þ
where R is the fraction of reduced Ero1a. The standard reduction
potential for the Ero1a regulatory disulphides could then be derived
from the Nernst equation [E10
(Ero1-La)¼E10
(Trx)–(RT/nF) In(Keq)]
using the calculated Keq from equation (1), T¼251C, n¼4 and
the standard reduction potential of Trx1¼ 270mV as determined
earlier (Krause and Holmgren, 1991).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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